Results 1 to 10 of about 71 (52)
WJOG18524G: A Single-Arm Phase II Study Evaluating Bemarituzumab Combined With Ramucirumab and Paclitaxel in Fibroblast Growth Factor Receptor 2b (FGFR2b)-Positive Advanced Gastric or Gastroesophageal Junction Cancer (RAINBIRD) [PDF]
ESMO Gastrointestinal OncologyBackground: Fibroblast growth factor receptor 2b (FGFR2)-overexpressing advanced gastric cancer (AGC) is associated with poor prognosis and limited treatment options.
Naoki Takahashi +2 more
exaly +6 more sources
ESMO Gastrointestinal OncologyBackground: In the phase II, randomized, double-blind FIGHT trial (NCT03694522), treatment with bemarituzumab plus mFOLFOX6 resulted in improvements in progression-free survival and overall survival relative to mFOLFOX6 alone in previously untreated ...
Ari Gnanasakthy +2 more
exaly +4 more sources
Ophthalmology and TherapyTargeted cancer therapies have transformed the landscape of cancer treatments but are often associated with off-target adverse drug reactions due to overlapping molecular pathways in healthy tissues, including those in the eye.
Asim V Farooq, Anita Zahlten-Kumeli
exaly +3 more sources
CellsGastric and gastroesophageal junction (G/GEJ) adenocarcinomas remain among the most aggressive and lethal malignancies globally. Most patients are diagnosed at advanced stages and respond poorly to conventional chemotherapy, highlighting the urgent ...
Dietrich Büsselberg, Peter Kubatka
exaly +4 more sources
Preclinical Characterization of Bemarituzumab, an Anti-FGFR2b Antibody for the Treatment of Cancer
MAbs, 2021 Bemarituzumab (FPA144) is a first-in-class, humanized, afucosylated immunoglobulin G1 monoclonal antibody (mAb) directed against fibroblast growth factor receptor 2b (FGFR2b) with two mechanisms of action against FGFR2b-overexpressing tumors: inhibition ...
Hong Xiang +2 more
exaly +3 more sources
The dawn of precision medicine in diffuse-type gastric cancer
Therapeutic Advances in Medical Oncology, 2022 Gastric cancer (GC) is one of the most common malignancies worldwide. The histology- and morphology-based Lauren classification of GC has been widely used for over 50 years in clinical practice.
Akira Ooki, Kensei Yamaguchi
doaj +2 more sources
New therapeutic targets in the management of advanced gastric cancer
Academia OncologyThe treatment of advanced gastric cancer remains challenging due to its late diagnosis and aggressive nature. HER2 inhibitors like trastuzumab deruxtecan (T-DXd) show significant efficacy in HER2-positive gastric cancer.
Paula Gomila Pons +2 more
doaj +1 more source
Current and Emerging Targeted Therapy in Advanced Gastroesophageal Adenocarcinoma
PharmaceuticalsBackground/Objectives: Advanced gastroesophageal adenocarcinoma (GEA) carries a poor prognosis, with median overall survival of 13–20 months despite standard chemotherapy.
Oliver Oakley +3 more
doaj +1 more source
CLDN18 and FGFR2 splicing variants are emerging tumor-associated antigens for cancer therapy
Frontiers in Molecular MedicineAlternative splicing and alternative promoters generate splicing variants to expand proteomic and transcriptional diversity to orchestrate physiological activities and dictate tumorigenesis.
Masuko Katoh, Masaru Katoh
doaj +1 more source
Some of the next articles are maybe not open access.